Caris Life Sciences, Inc. (CAI)

Market Cap	10.16B
Revenue (ttm)	533.85M
Net Income (ttm)	-798.58M
Shares Out	281.22M
EPS (ttm)	-18.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,313
Open	36.60
Previous Close	36.56
Day's Range	35.89 - 37.42
52-Week Range	25.40 - 42.50
Beta	n/a
Analysts	Strong Buy
Price Target	35.50 (-1.72%)
Earnings Date	Aug 12, 2025

About CAI

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising lab...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2025
• Employees: 1,769
• Stock Exchange: NASDAQ
• Ticker Symbol: CAI
• Website: https://www.carislifesciences.com

Financial Performance

In 2024, Caris Life Sciences's revenue was $412.26 million, an increase of 34.67% compared to the previous year's $306.13 million. Losses were -$378.26 million, -18.22% less than in 2023.

Financial numbers in USD

Analyst Summary

According to 6 analysts, the average rating for CAI stock is "Strong Buy." The 12-month stock price target is $35.5, which is a decrease of -1.72% from the latest price.

Price Target

$35.5

(-1.72% downside)

Analyst Consensus: Strong Buy